Breast Cancer Coverage from Every Angle

Jennifer K. Litton, MD: Patient Perspective on Talazoparib vs Chemotherapy for Breast Cancer

Posted: Monday, May 18, 2020

Jennifer K. Litton, MD, of The University of Texas MD Anderson Cancer Center, talks about why EMBRACA trial patients with BRCA1/2-mutated HER2-negative advanced disease preferred talazoparib over chemotherapy, even though the PARP inhibitor did not improve overall survival compared with standard treatment.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.